Integrating Current & Novel Treatment Strategies
for the Management of CRPC

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2017 to December 31, 2017

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Astellas Scientific & Medical Affairs

Description
Prostate cancer is the most commonly diagnosed solid organ malignancy in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 233,000 new cases diagnosed and 29,490 deaths in 2014. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients' disease progresses despite castrate levels of testosterone. Patients with all stages of CRPC have many treatment options available to them, from frontline therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. The treatment of mCRPC has dramatically changed over the past decade. Recent availability of emerging therapies for CRPC has given medical directors and physicians different studies on how to demonstrate improved survival with a variety of advanced therapeutic agents. Updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer. Despite recent advances, the prognosis for patients with CRPC with disseminated metastatic spread need improvement, with a significant impact on patients’ quality of life resulting predominantly from skeletal metastases. The updated therapeutic agents hope to continue to improve patient prognosis and quality of life by delaying metastatic spread and the need for highly toxic chemotherapeutic agents.

Upon Completion of this activity, participants will be able to:

  • Assess the safety, efficacy and the mechanism of action for systemic agents in the treatment of CRPC

  • Describe the updated guidelines and how they relate to the diagnostic and therapeutic decision making in the management of CRPC

  • Analyze novel agents used in the treatment of CRPC and their sequencing

  • Manage CRPC with systemic agents by learning the proper candidates for treatment and educate patients on the risks and benefits of therapies

  • Discuss the challenges and barriers of surgery vs. radiation based approaches for the management of CRPC
     

Faculty: Charles J. Ryan, MD
Professor of Clinical Medicine and Urology
Thomas Perkins Distinguished Professor in Cancer Research
Program Leader, Genitourinary Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Disclosure:

Dr. Ryan serves on advisory boards/consultants to AstraZeneca, Bayer and Ferring; receives research support from Kayopharm and is on the speakers’ bureau for Astellas and Janssen. His presentation has been peer reviewed. 
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by an educational grant from
Astellas Scientific & Medical Affairs

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue